Grifols (GIFLF) Operating Expenses (2009 - 2025)
Grifols' (GIFLF) quarterly Operating Expenses came in at -$1.9 million in Q4 2025, down 6.94% on a YoY basis from -$2.0 million in Q4 2024, and down 6.94% quarter-over-quarter from -$1.8 million in Q4 2024.
Analysis
Grifols (GIFLF) Operating Expenses (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Operating Expenses for 17 consecutive years, with -$1.9 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Operating Expenses fell 6.94% year-over-year to -$1.9 million; the trailing twelve-month figure through Dec 2025 stood at -$1.9 billion (down 6.97% YoY), and the FY2025 full-year result was -$1.8 billion, down 3.79% from the prior year.
- Operating Expenses retreated to -$1.9 million in Q4 2025 per GIFLF's latest filing, from -$1.8 million in the prior quarter.
- Across five years, Operating Expenses topped out at $122.3 million in Q4 2021 and bottomed at -$1.9 billion in Q4 2023.
- Historically, Operating Expenses has averaged -$356.7 million across 5 years, with a median of -$1.8 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses tumbled 5168671.1% in 2023, then surged 99.91% in 2024.
- Over 5 years, Operating Expenses stood at $122.3 million in 2021, then sank by 99.97% to $36804.4 in 2022, then sank by 5168671.1% to -$1.9 billion in 2023, then soared by 99.91% to -$1.8 million in 2024, then retreated by 6.94% to -$1.9 million in 2025.
- According to Business Quant data, Operating Expenses over the past three periods registered -$1.9 million, -$1.8 million, and -$1.9 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 6.54 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 18.20 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 2.09 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 3.00 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | -1.05 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 960.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 2.60 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 367.83 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | -1.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -1.87 Mn |
| Dec 31, 2024 | -1.75 Mn |
| Dec 31, 2023 | -1.90 Bn |
| Dec 31, 2022 | 36,804.40 |
| Dec 31, 2021 | 122.26 Mn |
| Dec 31, 2020 | 120.91 Mn |
| Mar 31, 2020 | -351.55 Mn |
| Dec 31, 2019 | -993.06 Mn |
| Mar 31, 2019 | -337.55 Mn |
| Dec 31, 2018 | -1.20 Bn |
| Jun 30, 2018 | 305.20 Mn |
| Mar 31, 2018 | -300.11 Mn |
| Dec 31, 2017 | -1.35 Bn |
| Jun 30, 2017 | 303.67 Mn |
| Mar 31, 2017 | -308.10 Mn |
| Dec 31, 2016 | -275.62 Mn |
| Sep 30, 2016 | 254.98 Mn |
| Jun 30, 2016 | 278.46 Mn |
| Mar 31, 2016 | 103.56 Mn |
| Dec 31, 2015 | -1.81 Bn |